2 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow Hdm201: new trials by email Literature Review of Hdm201 trials Research Report on Hdm201
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant Siremadlin - Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 8 | 2023-02-23 | 2025-05-16 |
| Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Ruxolitinib, Siremadlin, Crizanlizumab - Myelofibrosis | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 45 | 2019-09-26 | 2025-08-07 |
Leukemia, Myeloid, Acute (1) · Primary Myelofibrosis (1)
Germany (2) · Italy (2) · Spain (2) · Australia (1) · Canada (1) · Denmark (1) · Hungary (1) · Netherlands (1) · Russia (1) · Sweden (1) · Switzerland (1) · Turkey (Türkiye) (1) · United Kingdom (1)
2019 (1)